Repeat treatment of rheumatoid arthritis patients with a murine anti- intercellular adhesion molecule 1 monoclonal antibody

Arthritis and Rheumatism

Volumn 40, Issue 5, 1997, Pages 849-853

  Kavanaugh, Arthur F ^a   Schulze Koops, Hendrik ^a   Davis, Laurie S ^a   Lipsky, Peter E ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; MONOCLONAL ANTIBODY;

ABDOMINAL CRAMP; ANGIONEUROTIC EDEMA; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; HEADACHE; HUMAN; HUMAN CELL; IMMUNE COMPLEX DEPOSITION; IMMUNOGENICITY; MYALGIA; NAUSEA; OPSONIZATION; PETECHIA; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; URTICARIA;

EID: 0030911156     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.1780400511     Document Type: Article

References (11)

1. Kavanaugh AF, Davis LS, Nichols LA, Norris SH, Rothlein R, Scharschmidt LA, Lipsky PE: Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1. Arthritis Rheum 37:992-999, 1994
2. Kavanaugh AF, Davis LS, Jain RI, Nichols LA, Norris SH, Lipsky PE: A phase I/II open label study of the safety and efficacy of an anti-ICAM-1 (intercellular adhesion molecule-1; CD54) monoclonal antibody in early rheumatoid arthritis. J Rheumatol 23:1338-1344, 1996
3. Davis LS, Kavanaugh AF, Nichols LA, Lipsky PE: Induction of persistent T cell hyporesponsiveness in vivo by monoclonal antibody to ICAM-1 in patients with rheumatoid arthritis. J Immunol 154:3525-3537, 1995
4. Schulze-Koops H, Lipsky PE, Kavanaugh AF, Davis LS: Elevated Th1- or Th0-like cytokine mRNA in peripheral circulation of patients with rheumatoid arthritis; modulation by treatment with anti-ICAM-1 correlates with clinical benefit. J Immunol 155:5029-5037, 1995
5. Schulze-Koops H, Lipsky PE, Kavanaugh AF, Davis LS: Persistent reduction in IL-6 mRNA in peripheral blood mononuclear cells of patients with rheumatoid arthritis responding to treatment with a monoclonal antibody to CD54 (ICAM-1). Clin Exp Immunol 106:190-196, 1996
6. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA Jr, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315-324, 1988
7. Cosimi AB, Conti D, Delmonico FL, Preffer FI, Wee S-L, Rothlein R, Faanes R, Colvin RB: In vivo effects of monoclonal antibody to ICAM-1 (CD54) in nonhuman primates with renal allografts. J Immunol 144:4604-4611, 1990
8. Paulus HE, Egger MJ, Ward JR, Williams HJ, and the Cooperative Systematic Studies of Rheumatic Diseases Group: Analysis of improvement in individual rheumatoid arthritis patients treated with disease modifying antirheumatic drugs, based on the findings in patients treated with placebo. Arthritis Rheum 33:477-484, 1990
9. Lawley TJ, Bielory L, Gascon P, Yancey KB, Young NS, Frank MM: A prospective clinical and immunologic analysis of patients with serum sickness. N Engl J Med 311:1407-1413, 1984
10. Mannik M: Serum sickness and pathophysiology of immune complexes. In, Clinical Immunology; Principles and Practice. Edited by RR Rich, TA Fleisher, WT Shearer, BD Schwartz, W Strober. St Louis, Mosby, 1996
11. Rothlein R, Kishimoto TK, Mainlofi E: Cross-linking of ICAM-1 induces co-signalling of an oxidative burst from mononuclear leukocytes. J Immunol 152:2488-2495, 1994